Employers start dropping GLP-1 weight-loss coverage a year after widely adding it
Business Group on Health's survey finds at least 10% of employer plans covering GLP-1 weight-loss drugs likely to drop them in 2027. About two-thirds of private employer plans covered them in 2026, and each exit now leaves workers to pay cash or stop.
The Board Room · Leadership desk
6 percent of large employers in a Mercer survey dropped GLP-1 coverage in 2026; at least 10 percent of covering plans are likely to drop it in 2027, per Business Group on Health; Massachusetts commercially insured people on a GLP-1 fell 50 percent from 2025 to Q1 2026.
| Figure | Value | Note | Claim |
|---|---|---|---|
| Large employers dropping coverage in 2026, Mercer | 6% | 4 | |
| Covering plans likely to drop in 2027, at least | 10% | Business Group on Health survey | 3 |
| Drop in Massachusetts commercially insured on GLP-1s | 50% | 2025 to first quarter of 2026 | 5 |
What happened
- In Mercer's survey of large employers, 6 percent dropped coverage in 2026, and another 5 percent either plan to drop it in 2027 or are weighing doing so.
- Vox reports that some of the biggest US brands, PepsiCo among them, are reportedly eliminating or reducing their GLP-1 coverage.
- Over the summer, Medicare launched a new $50-per-month prescription program.
Why it matters
- What it costs cost Where a plan exits, the worker either pays a cash price that runs to hundreds of dollars a month or stops a drug they feel is helping, and the lower the income, the harder that choice.
- What it limits constraint Job turnover weakens an employer's reason to pay for benefits that return value over decades, so a coverage case built on long-run savings has to clear a one-year budget.
- Who has to decide decision Employers deciding 2027 coverage this quarter will see the effect on workers only in later prescription data, so the first reading on a drop arrives after the decision is made.
Mercer's two figures add to 11 percent of the large employers it surveyed [15]. Only the first, 6 percent, is a completed decision. The other 5 percent includes employers that are still "actively considering" a change [4]. Vox adds that the Business Group on Health count may still increase [3]. Even so, the retreat is small beside the climb that preceded it, because coverage roughly tripled in a year, from about 20 percent [16].
The Massachusetts figure is much larger. Commercially insured people taking a GLP-1 drug there fell 50 percent between 2025 and the first quarter of 2026, according to the state's Health Policy Commission, as private coverage started to drop off [5]. The two numbers are not comparable. One counts patients in one state, and the other counts large employers in a survey [4][5]. We do not know yet how much of the Massachusetts fall traces to employer decisions, or whether one state's experience predicts the national one.
Eli Lilly frames coverage as an investment case. Laura Steele, who leads the cardiometabolic health unit at Lilly, which makes Zepbound and Foundayo [10], said: "They're recognizing that this is an investment in their workforce." [11] Lilly sells the drugs, and Steele also granted the limit: "Yes, there is a budget, and there is a benefit design that every employer has. That's real. That's not going away." [12] That budget is what employers and insurers are weighing as they make coverage decisions for next year [13].
The investment case runs on a long clock. Vox's account is that over a full lifetime the drugs could help people lose weight and lower their risk of heart disease, kidney disease and other chronic problems, saving money as they age [18]. Dan Sacks, a healthcare economist at the University of Wisconsin-Madison, said an employer or an insurer making coverage decisions does not necessarily care whether it is saving Medicare money. He called that a classic problem with the American health insurance system, and said it is certainly salient here [14].
What to watch
- Whether the Business Group on Health count rises above 10 percent as employers finalize 2027 plans, which Vox says it may.
- Whether the 5 percent of Mercer's large employers that are planning or considering a drop turn into completed decisions.
- Whether prescription counts from states other than Massachusetts show a fall in commercially insured GLP-1 users like the 50 percent drop there.
Clarity's read
What the record supports and how the coverage leans. The claims behind it follow.
Reality
- Evidence58
- Adoption60
- Hype gap+15
- Incentives55
- Confidence55
Claim ledger
Ranked by verification strength, evidence, and original report placement.
- [1]
As of 2026, roughly two-thirds of private employer plans, which insure half of Americans, were covering GLP-1 medications for weight loss to treat obesity.
- [2]
In 2026, about two out of every three employer-sponsored plans were covering some GLP-1 drugs for weight management, up from about 20 percent the year before.
- [3]
At least 10 percent of employer plans that currently cover GLP-1s for weight loss say they are likely to discontinue coverage in 2027, according to a Business Group on Health survey; Vox adds that the number may still increase.
- [4]
A Mercer survey of large employers found that 6 percent had dropped GLP-1 coverage in 2026 and another 5 percent were planning to in 2027 or actively considering it.
- [5]
A Massachusetts Health Policy Commission report found the number of commercially insured people in the state taking a GLP-1 drug fell by 50 percent between 2025 and the first quarter of 2026 as private coverage started to drop off.
- [6]
Over the summer, Medicare launched a new $50-per-month prescription program.
- [7]
GLP-1 drugs still cost hundreds of dollars per month if paid for in cash, and a low-income worker who needs the drug to lose significant weight might not be able to afford them unless insurance covers it.
- [8]
People are debating whether to pay for GLP-1 drugs on their own or stop taking medicines they feel are making a real difference for their health.
- [9]
Because people no longer stay at the same job for decades, employers have little financial incentive to invest in long-term health benefits but a strong incentive to minimize short-term costs.
- [10]
Laura Steele leads the cardiometabolic health unit at Eli Lilly, which manufactures Zepbound and Foundayo.
- [11]
They're recognizing that this is an investment in their workforce.
- [12]
Yes, there is a budget, and there is a benefit design that every employer has. That's real. That's not going away.
- [13]
As employers and private insurers make coverage decisions for next year, they are pulling back from GLP-1 coverage.
- [14]
An employer or an insurer making coverage decisions doesn't necessarily care if they're saving Medicare money. That's a classic problem with the American health insurance system, and it's certainly salient here.
- [15]
Mercer's two figures sum to 11 percent of the large employers surveyed: 6 percent that dropped coverage in 2026 plus 5 percent planning or considering a drop in 2027.
- [16]
Employer coverage of GLP-1 weight-loss drugs roughly tripled in a year, from about 20 percent to about two-thirds.
- [17]
Some of the biggest brands in the US, PepsiCo among them, are reportedly eliminating or reducing their GLP-1 coverage.
- [18]
Taken over the full course of a person's life, GLP-1 drugs could help people lose weight and reduce their risk of heart disease, kidney disease and other chronic health problems, saving money as they get older.
Get this ledger inside ChatGPT. Ask about any of our stories and the answer brings its figure, each claim’s verdict and the sources. Free, no account.
Sources
1 independent publisher whose own reporting we read for this story.
- vox.comWhy your health insurance is dropping GLP-1 coverage
1 article · October 15, 2026
Topics and entities
Follow any of these and your For You feed starts watching them — no settings page required.
Topics
- Employer health insuranceFollow
- GLP-1 drugsFollow
- Obesity treatment coverageFollow